Biotech IPO market looks to ramp back up as BMS partner Ikena and its immunometabolism therapies eye public offering

Ikena Oncology, formerly known as Kyn Therapeutics, submitted its S-1 paperwork Friday penciling in a $100 million to jump to Nasdaq. The company’s lead in-house candidate has not yet reached the clinic, but it’s working with BMS and Merck on a couple tumor microenvironment programs that have already hit Phase I.